04:32 AM EDT, 09/24/2025 (MT Newswires) -- Monopar Therapeutics ( MNPR ) said Tuesday it priced a $135 million offering, consisting of over 1 million common shares at $67.67 and pre-funded warrants for roughly 960,000 shares at $67.669 each.

The company expects net proceeds of approximately $100 million after underwriting discounts and expenses, which will be used for general corporate purposes, including research and development, clinical trials, and working capital, it said.

Monopar also plans to use up to $35 million of the proceeds to repurchase common stock from Tactic Pharma at $63.61 per share, the company said.

The offering is expected to close around Thursday, subject to customary closing conditions, Monopar added.